接受替莫唑胺和免疫检查点抑制剂治疗的患者可能会出现淋巴细胞减少症，这可能是 COVID-19 爆发期间死亡的高风险因素。
Lymphopenia that may develop in patients treated with temozolomide and immune control check-point inhibitor may be a high risk for mortality during the COVID-19 outbreak.
机构信息
Department of Medical Oncology, Faculty of Medicine, Mugla Sitki Kocman University, Mugla, Turkey.
Department of Molecular Biology and Genetics, Graduate School of Natural and Applied Sciences, Mugla Sitki Kocman University, Mugla, Turkey.
出版信息
Med Oncol. 2020 Apr 24;37(6):51. doi: 10.1007/s12032-020-01376-8.
As we know more about the clinical and laboratory features of COVID-19, which is now accepted as a pandemic, many questions have been raised about how to manage and monitor the treatment of cancer patients. It was determined that the incidence of lymphopenia increased in COVID-19 and there was a significant relationship between lymphopenia and mortality. This can be thought of as an unresponsive problem in how to maintain anti-cancer drugs that cause lymphopenia. This article was written for a hypothetical approach in cancer patients diagnosed with COVID-19 in order to be an idea of collecting data for treatment with anti-cancer drugs that cause lymphopenia.
随着我们对 COVID-19（现已被认定为大流行疾病）的临床和实验室特征有了更多了解，人们对如何管理和监测癌症患者的治疗提出了许多问题。现已确定 COVID-19 患者的淋巴细胞减少症发病率增加，且淋巴细胞减少症与死亡率之间存在显著关系。这可以被认为是在维持引起淋巴细胞减少症的抗癌药物方面存在的一个无反应性问题。本文旨在为诊断患有 COVID-19 的癌症患者提供一种假设性的治疗方法，以便为治疗引起淋巴细胞减少症的抗癌药物收集数据提供思路。
Zotero 插件